Navigation Links
Trubion Announces Initiation of Phase 1 Study of SBI-087 for the Treatment of Rheumatoid Arthritis
Date:4/21/2008

Section 21E of the Securities Exchange Act of 1934 and Section 27A of the Securities Act of 1933. These statements include, but are not limited to, those related to the company's future clinical development programs and the timing thereof, the company's expected financial and operating results, future clinical development plans, the details of the clinical trials and the results and timing thereof, and the timing of regulatory applications and action. These statements are based on current expectations and assumptions regarding future events and business performance and involve certain risks and uncertainties that could cause actual results to differ materially. These risks include, but are not limited to, risks associated with the company's Wyeth collaboration, including Wyeth's control over development timelines, the risks that the Company is unable to advance its clinical development programs and regulatory applications and action at the rate it expects, the risk that the Company does not achieve the financial and operating results it expects and such other risks as identified in the company's quarterly report on Form 10-K for the period ended December 31, 2007, and from time to time in other reports filed by Trubion with the U.S. Securities and Exchange Commission. These reports are available on the Investors page of the company's corporate Web site at http://www.trubion.com. Trubion undertakes no duty to update any forward-looking statement to conform the statement to actual results or changes in the company's expectations.

For more information, contact:

Trubion Pharmaceuticals Inc.

Jim DeNike

Senior Director, Corporate Communication

(206) 838-0500

jdenike@trubion.com

Waggener Edstrom Worldwide Healthcare

Amy Petty

Senior Account Executive

(617) 576-5788


SOURCE Trubion Pharmaceuticals Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Trubion Announces Preliminary Analysis of Phase IIb Results With TRU-015 in Rheumatoid Arthritis
2. Trubion Pharmaceuticals Announces Presentation of Positive Data From Phase IIb and Re-treatment Studies With TRU-015 in Patients With Rheumatoid Arthritis
3. Trubion Announces Initiation of Phase I/II Clinical Trial of TRU-015 for the Treatment of B-Cell Non-Hodgkins Lymphoma
4. Trubion Initiates Phase 1/2 Study of TRU-016 in CLL, Announces Next-Generation Product Candidate for RA and Provides Product Pipeline Update
5. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
6. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
7. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
8. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
9. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
10. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
11. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... EVANSVILLE, Ind. , Sept. 16, 2014   ... builder of custom, automated assembly and test systems, recently ... for a leading medical device manufacturer. The Evana solution ... improve quality and ergonomics, as well as reduce labor. ... are automatically fed to Evana,s robotic assembly cell. The ...
(Date:9/16/2014)... 16, 2014   Vestagen Technical Textiles, Inc. ... at hospitals. The myComfort™ line of patient apparel is ... that is fluid repellant, breathable and in studies done ... of bacteria on the fabric i . ... the chain of transmission. We want myComfort to be ...
(Date:9/16/2014)... 16, 2014  Synereca Pharmaceutics, Inc. (SPI), ... active drugs that restore or increase the ... $1.4 million convertible debt financing. Accele Venture ... accelerator Accele Biopharma, Inc., led the financing ... recognized private not-for-profit corporation focused on growing ...
Breaking Medicine Technology:Evana Automation to Supply Robotic Assembly Cell to Leading Medical Device Manufacturer 2Evana Automation to Supply Robotic Assembly Cell to Leading Medical Device Manufacturer 3New Vestagen Patient Garments Aim to Minimize Pathogen Transmission Inside Hospitals 2Synereca Pharmaceuticals Announces Financing Led by Accele Venture Partners 2Synereca Pharmaceuticals Announces Financing Led by Accele Venture Partners 3Synereca Pharmaceuticals Announces Financing Led by Accele Venture Partners 4
... Council (NPC) today welcomed global specialty biopharmaceutical company Shire ... senior vice president, specialty pharma R&D, will serve as ... "The last few years have brought change ... important questions unresolved.  For the pharmaceutical industry, how ...
... Medical, Inc., a Minnesota-based medical device company, has announced that ... eripheral F acilitated A ntegrade S teering ... O cclusions (PFAST-CTOs) study.  The company received approval from ... US based IDE for the peripheral devices and is now ...
Cached Medicine Technology:National Pharmaceutical Council Welcomes Shire as Its Newest Member 2BridgePoint Medical Announces US IDE Approval and First Patient Enrollment of Peripheral Chronic Total Occlusion Study 2
(Date:9/16/2014)... An experienced review website, Top10BestSEOHosting.com, has recently ... Bluehost and HostGator.com are among the best hosting ... high quality web hosting (including VPS and cloud ... now. , BlueHost ( http://www.bluehost.com/track/seohosts ) has ... a reliable and long-standing force in the world ...
(Date:9/16/2014)... The second federal bellwether trial involving ... subsidiary Ethicon concluded with the jury in the case ... her $3.27 million in damages, according to a September ... found Ethicon liable for selling faulty devices and failing ... at risk from side effects that include pain, bleeding ...
(Date:9/16/2014)... HealthDay Reporter TUESDAY, Sept. 16, 2014 ... human papillomavirus (HPV), which is linked to the risk of ... that testing urine for HPV has good accuracy when compared ... lead researcher Dr. Neha Pathak. She is a resident in ... of London, England. The test could be done at ...
(Date:9/16/2014)... September 16, 2014 Not all recovery ... take care to make sure all their patients are ... some, this may include the newly-introduced online therapy. Millennium ... which gives patients the opportunity to seek treatment from ... provide medical and clinical care at a distance. They ...
(Date:9/16/2014)... in helping people to reach their fitness and ... wearers improve their wellness by constantly monitoring their ... into companion computer programs and mobile apps. ... for these devices, researchers at the University of ... these activity monitors, such as those made by ...
Breaking Medicine News(10 mins):Health News:Top10BestSEOHosting.com: BlueHost and HostGator.com Are Among the Best Hosting Suppliers in 2014 2Health News:Ethicon to Appeal Bellwether Trial Verdict of $3.27 Million, Rottenstein Law Group LLP Notes 2Health News:Urine Test for HPV Works Well, Analysis Finds 2Health News:Millennium Treatment Group Now Offers Online Therapy 2Health News:Do wearable lifestyle activity monitors really work? 2Health News:Do wearable lifestyle activity monitors really work? 3
... , ST. LOUIS, Aug. 24 Recent developments ... have attorney and clean water advocate Steve Tillery cautiously optimistic ... for the herbicide,s manufacturers. , , "Just ... York Times and the Peoria Journal Star have underscored the ...
... attack and stroke, but also prevent them. Scientists at Heidelberg ... for the first time on an animal model. Mice with ... in their vessels, but they are more stable. Thus, there ... circulation. The results of the study have been published in ...
... (BRONX, NY) - Concussions, whether from an accident, sporting ... higher level mental processes. Scientists have debated for centuries ... whether physiological changes that merely impair the way brain ... time, researchers at Albert Einstein College of Medicine of ...
... New Rochelle, NY, August 24, 2009Twitter, the increasingly popular ... convenient way to stay in touch with friends and ... real-time, on-the-go communication of healthcare information and medical alerts, ... Connectivity section of the latest issue of Telemedicine ...
... signals future heart risk, researcher says. , MONDAY, Aug. 24 ... women may also show if they have an increased risk ... found. , This finding is important because doctors might be ... to identify women who are at risk for developing heart ...
... , , CINCINNATI Aug. 24 The Kroger ... it easy and affordable for customers to take steps to keep ... , , This year, Kroger,s more than 1,900 ... at an affordable price. Beginning in September, flu vaccines will ...
Cached Medicine News:Health News:Korein Tillery: Is Time Running Out for the Manufacturers of the Herbicide Atrazine? 2Health News:Korein Tillery: Is Time Running Out for the Manufacturers of the Herbicide Atrazine? 3Health News:Why 'thick' blood protects from a heart attack 2Health News:Strong link found between concussions and brain tissue injury 2Health News:Strong link found between concussions and brain tissue injury 3Health News:Twitter and health care -- can a tweet a day keep the doctor away? 2Health News:Glucose Challenge in Pregnancy Could Predict Heart Disease 2Health News:Kroger's Family of Pharmacies Offer Customers Easy and Affordable Seasonal Flu Vaccinations 2
Used to introduce balloon, electrode, closed or non-tapered end catheters and other devices for intervention....
Used to introduce balloon, closed and non-tapered end catheters or other devices for intervention....
Sheath Introducers with guidewires....
Used to introduce balloon, electrode, closed or non-tapered end and,other catheters....
Medicine Products: